PUMA BIOTECHNOLOGY, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $228.4M | $230.5M | $235.6M | $228.0M | $253.2M |
| Operating income | $37.3M | $31.0M | $32.6M | $23.7M | $1.3M |
| Cost of revenue | $58.2M | $64.4M | $62.7M | $55.1M | $63.7M |
| Cash from operations | $41.8M | $38.9M | $27.0M | -$15.8M | $20.6M |
| Capital expenditure | $71,000 | $56,000 | $140,000 | $0 | $0 |
| Free cash flow | $41.7M | $38.9M | $26.9M | -$15.8M | $20.6M |
| Impairments | $0 | $0 | $625,000 | $0 | $0 |
| Total assets | $216.3M | $213.3M | $230.5M | $222.1M | $226.6M |
| Total liabilities | $86.0M | $121.2M | $177.1M | $200.5M | $229.0M |
| Total debt | $102.0M | $102.0M | $102.0M | $102.0M | $102.0M |
Shares outstanding 50.9M · Free float 83.3%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.